This common molecule could reverse muscle ageing and prevent frailty, scientists say
The populations of developed countries are getting older, leading to higher rates of associated frailty and debilitation among their people.
Gradual muscle loss in these populations is accelerated by the poor capacity of muscle tissues in older people to repair injury, especially after falls or surgeries.
This leads to a condition called sarcopenia, or low muscle mass, in older people, making them prone to even more frailty and movement problems.
Previous studies have shown that muscle stem cells play a key role in repairing such tissue damage, but they become dysfunctional with age.
Researchers have been trying to understand how aged stem cells differ from young ones and to find ways to reverse these changes.
A new study, published in the journal Cell Stem Cell, reveals that aged mice treated with a naturally occurring molecule in the body called Prostaglandin E2 (PGE2) show improved regeneration and strength of aged muscle.
Scientists also found that the PGE2 molecule works by counteracting stem cell ageing.
In the study, researchers examined the effects of PGE2 and its related molecule EP4 on the body.
Previous research has shown that during muscle injury, PGE2 triggers muscle stem cells to regenerate the muscles of young mice.
In aged mice, scientists found that the EP4 production in muscle stem cells was either lacking, or reduced by half compared to levels found in young stem cells.
'PGE2 is an alarm clock to wake up the stem cells and repair the damage. Aging essentially reduces the volume of the alarm and the stem cells have also put on ear plugs,' said study author Yu Xin Wang.
The new research has found a way to reset the intensity of this cellular alarm clock.
When scientists gave a stable form of PGE2 to aged mice after muscle injury and in conjunction with exercise, they found that the treated mice gained more muscle mass and were stronger compared to untreated ones.
'What amazes me most is that a single dose of treatment is sufficient to restore muscle stem cell function, and that the benefit lasts far beyond the duration of the drug,' Dr Wang said.
'In addition to making new muscle, the stem cells stay in the tissue, where they sustain the effect of the PGE2 and instil the muscle with further capacity to regenerate,' he said.
The study found that PGE2 treatment can restore stem cell function and reverse many of the age-related changes in mice muscles.
'PGE2 has been implicated in the regenerative process and signalling for the intestine, liver, and several other tissues, potentially opening up an approach that could restore the renewing capacity of other aged tissues,' Dr Wang said.
'We have discovered that the PGE2 induces rejuvenation of aged muscle stem cells, which leads to functional improvements in muscle repair and strength,' scientists concluded.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
33 minutes ago
- BBC News
Warning issued over kids' magnesium supplement gummies
Parents are being warned to stop using Nutrition Ignition Kids Magnesium Glycinate Gummies, due to them containing an undeclared drug called melatonin that could cause issues for is a prescription-only medicine, which can cause drowsiness, headaches, dizziness and of two batches by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) found the products, which have now been pulled from sale, contained between 1.5mg and 1.7mg of who has given the product to a child is advised to speak to a healthcare professional if they notice any adverse side effects, although lasting harm is not expected. Melatonin can be given to children over the age of six for sleep management if other methods have is often used for children with attention deficit hyperactivity disorder (ADHD) or delayed sleep wake phase disorder (DSWPD) and for the short-term treatment of insomnia. Children can be prescribed a starting dose of 1mg, up to 5mg of melatonin per day and no serious side effects have been identified in studies of gummies in question were recommended for children above the age of four to help support "calm, focus and digestion".Magnesium glycinate is supposed to help support muscle function, improve sleep quality and regulate the body's nervous are being advised to dispose of the item at a local pharmacy and report any side effects to the MHRA Yellow Card Nutrition Ignition brand website has now been deleted and products have been removed from online retailers such as Amazon and reported by The Guardian in June, the gummy brand was owned by Surrey-based NHS clinical therapy lead Sally was ordered to remove the raspberry-flavoured gummies from sale more than a month ago by the MHRA after they were alerted to the sweets' hidden ingredients by two concerned women had the gummies tested when they noticed their young children falling asleep more quickly than usual after consuming them and it was then discovered that they contained melatonin. Westcott, who is yet to comment on the MHRA report, said in June that she had "never knowingly sold products containing undeclared ingredients".
Reuters
2 hours ago
- Reuters
Affidea Partners With Skin Analytics to Improve Access to Skin Cancer Assessment Across Europe Using AI Technology
THE HAGUE, Netherlands, August 18, 2025 (EZ Newswire) -- Affidea, opens new tab, a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including oncology, has entered a strategic partnership with Skin Analytics, opens new tab, a pioneering AI company in dermatology care. This collaboration supports Affidea's long-term vision of leveraging digital innovations to improve patient outcomes as part of its integrated skin cancer care pathway. As part of this partnership, Affidea has implemented Skin Analytics' DERM, an AI medical device software for the automated analysis of skin lesions. The initial implementation of DERM began in Romania and Lithuania, with Greece to follow in September. These countries were selected based on market analysis, clinical readiness and innovation focus. The aim is to improve patient access to high quality care by introducing clinically validated AI technology into the gold standard skin care pathway already in place. This enables patients' triage while streamlining workflows. Following this first phase, Affidea plans to roll out the AI solution across additional European markets. Dr. Charles Niehaus, executive director for Affidea Group, stated: "Integrating cutting-edge digital innovations into clinical practice is essential to delivering the best possible care for our patients. Our partnership with Skin Analytics marks an exciting milestone, enabling us to leverage AI in supporting early detection of skin cancer and to provide even more patients with access to the prevention, diagnosis, and treatment programs we already offer in our dermatology units. This collaboration is not just about introducing new technology — it's about creating scalable, sustainable solutions that empower patients and clinical teams, address rising demand and bring timely, high-quality care across Europe." Neil Daly, founder and CEO of Skin Analytics, stated: 'We're incredibly proud to be partnering with Affidea as our first European partner. This collaboration represents a major milestone in our mission to transform access to dermatology care using AI. By combining Affidea's clinical excellence and pan-European reach with our proven technology, DERM, we have an opportunity to reimagine how skin cancer is identified and managed across the continent. At scale, this partnership will drive earlier diagnoses, improve access to care and support dermatology teams facing rising demand — ultimately marking history for how skin cancer care is delivered and improving outcomes for patients across Europe.' Skin cancer remains a significant public health challenge across Europe. According to GLOBOCAN 2022 data, Europe accounts for approximately 10.4 melanoma cases per 100,000 people. Non-melanoma skin cancers were even more prevalent, with over 1.15 million cases in Europe in 2022 [1]. This burden continues to grow — age-standardised incidence rates for melanoma have risen sharply over the past decades, and non-melanoma cases now represent nearly 78% of all skin cancer diagnoses. Source [1] Global Cancer Observatory, International Agency for Research on Cancer: opens new tab About Affidea Group Affidea is a leading pan-European provider of specialist healthcare services, including cancer care, community-based polyclinics and advanced diagnostic imaging. Founded in 1991, the company operates over 410 centres across 15 countries, with more than 14 million patient visits every year. Affidea is majority-owned by Groupe Bruxelles Lambert (GBL), a leading investment holding company, focused on long-term value-creation with a stable and supportive family shareholder base. For more information, visit opens new tab. For media inquiries regarding Affidea Group, contact opens new tab. About Skin Analytics Skin Analytics was founded in 2012 by Neil Daly to help more people survive cancer. It began providing teledermatology services in 2015 and since 2020 is now deployed in 27 NHS sites across the UK, having seen more than 180,000 NHS patients and detected more than 15,500 cancers. Post-market surveillance has shown that DERM found 97% of cancers (and accurately identified over 75% of benign lesions) with a negative predictive value (NPV) of 99.6% for all skin cancers. Settings in which DERM has been deployed have been able to reduce the number of face-to-face dermatologist appointments required for the volume of suspected skin cancer referrals by 60 to 95%, and DERM can autonomously discharge up to 40% urgent suspected skin cancer referrals. DERM is the only Class III CE marked AI Dermatology medical device, enabling Skin Analytics to begin actively expanding its lifesaving services to Europe. For more information, visit opens new tab. For media inquiries regarding Skin Analytics, contact skin@ opens new tab. About DERM DERM is an AI medical device (AIaMD), operating under a Class III CE mark. DERM is intended for use in the screening, triage and assessment of skin lesions suspicious for skin cancer. DERM will analyse a dermoscopic image of a skin lesion and return a suspected diagnosis and, if applicable, a referral recommendation for the lesion. DERM is indicated for use on dermoscopic images of cutaneous lesions where there is a suspicion of skin cancer in patients aged 18 years or over in any body location except where specific exclusions apply. Deployed across NHS sites in the UK, Skin Analytics pathways have seen more than 180,000 patient cases and supported the identification of over 15,500 cancers. With a negative predictive value rate of 99.9% for ruling out melanomas, the platform has become a proven tool for aiding clinical decision-making while enhancing patient access and efficiency within skin cancer pathways. Media Contact Oana ### SOURCE: Affidea Group Copyright 2025 EZ Newswire See release on EZ Newswire
The Sun
2 hours ago
- The Sun
Eating mango could be ‘beneficial' for millions of Brits living with silent killer condition
EATING mangoes could be "beneficial" to people with type 2 diabetes, research suggests. Of the millions of Brits living with the condition, many might assume that mango is off the menu. The sweet fruit has a reputation for spiking blood sugar levels, leading some diabetics to avoid it altogether. Others fall to the opposite extreme of thinking that gorging on mangoes in excess might "reverse diabetes". New research suggests that mangoes might not be the villain they're made out to be - but "this is not a licence for unlimited mango feasts", scientists stress. Two new clinical trials from India - where mangoes are considered the "king of fruits" - that eating mangoes while abstaining from carbohydrates like bread may actually improve blood sugar and metabolic health in people with type 2 diabetes. It's thought that 4.6 million people in the UK have a diabetes diagnosis, while 1.3 million have type 2 diabetes but don't know it. A further 6.3 million have prediabetes, which can turn into type 2 diabetes if left untreated, according to Diabetes UK. Type 1 diabetes occurs when the pancreas produces little or no insulin, while in type 2, the body becomes resistant to insulin's effects. A study of 95 people soon to be published in the European Journal of Clinical Nutrition found that three popular Indian mango varieties - Safeda, Dasheri and Langra - produced similar or lower glycaemic responses to white bread two hours after eating. A glycaemic response refers to how much and how quickly carby foods are absorbed into the blood stream as glucose, raising blood sugar. Continuous glucose monitoring of people with and without type 2 diabetes over three days showed that people with type 2 diabetes had significantly smaller post-meal sugar fluctuations when swapping bread for mango. 40 Day Health Challenge GP Dr Sumi Dunne on signs and symptoms of diabetes to watch out for This low fluctuation glycaemic response could be beneficial to the body in the long run, researchers said. Dr Sugandha Keha, the author of both studies, said: "These studies show that within prescribed diets, consumption of mangoes are not detrimental to blood glucose and may even be beneficial." "Mangoes are a much-loved fruit and maligned for their possible glucose and weight-elevating effects. "These studies show that within prescribed diets, consumption of mangoes are not detrimental to blood glucose and may even be beneficial." These findings suggest that a measured serving of mango can be incorporated into a meal plan without worsening short-term glucose control, according to A second eight-week trial of thirty-five adults with type 2 diabetes, published in the Journal of Diabetes & Metabolic Disorders, echoed these findings. Participants who replaced their breakfast bread with 250g of mango saw improvements in fasting glucose, average blood sugar levels, insulin resistance, weight, waist circumference and cholesterol. Prof Anoop Misra, senior author and study lead: "We showed the benefits of small doses of mangoes in place of carbohydrates (bread) in breakfast in two detailed studies for the first time, laying to rest all speculations regarding adverse metabolic effects of its consumption. "But the key is moderation and clinical supervision - this is not a licence for unlimited mango feasts." Prof Misra explained what eating mangoes in moderation meant. He told the BBC: "If your daily limit is 1,600 calories, any calories from mango should be part of that total, not extra. "A 250g mango - about one small fruit - has roughly 180 calories. "As in the study, you'd replace an equivalent amount of carbs with mango to get the same results." Mumbai-based diabetologist Dr Rahul Baxi added to this. "If glucose levels are under control, I do allow and even encourage my patients to enjoy mangoes in limited quantities - about half portion which gives 15g carbohydrates - once or twice a day," he told the BBC Portion control is key, he added, and mangoes should be eaten between meals, not as dessert. Dr Baxi advised pairing them with protein or fibre, and to avoid combining with other carbs or in juices and milkshakes. "The consistent message across [studies] is substitution," said. "Mango took the place of bread. It did not sit alongside it. "If you add [a 250 g serving of mango] to a meal that already includes bread or rice you will increase both carbohydrate and energy, which is likely to raise glucose and total intake." It advised pairing mango with plain yoghurt, cottage cheese, nuts or seeds to up the protein and fibre content, slow digestion and smooth the rise in glucose. Timing is something to think about too - having mango with or between meals usually works better than a large dessert after a heavy, carbohydrate-rich meal. "These studies relate to type 2 diabetes," stressed. "They do not tell us how mango fits for people with type 1 diabetes, where carbohydrate counting and insulin dosing are required for every carbohydrate-containing food." It comes after a drug that slows down the development of type 1 diabetes was licensed for use in the UK last week.
